

PROVIDER BULLETIN

PROVIDER INFORMATION



November 6, 2017

Clarification to Commercial Prior Authorization Requirements for Biologic Immunomodulators

Effective December 18, 2017, medical policy II-170: Biologic Immunomodulators: Abatacept (Orencia®), Certolizumab Pegol (Cimzia®), Golimumab (Simponi Aria®), Tocilizumab (Actemra®), Ustekinumab (Stelara®), and Vedolizumab (Entyvio®) will be replaced with the following 6 separate policies:

- II-161: Abatacept (Orencia®)
- II-179: Certolizumab (Cimzia®)
- II-180: Golimumab (Simponi Aria®)
- II-181: Tocilizumab (Actemra®)
- II-168: Ustekinumab (Stelara®)
- II-182: Vendolizumab (Entyvio®)

Due to this change, the Commercial Pre-Certification/Pre-Authorization/Notification List will be updated as follows:

- Reference to II-170: Biologic Immunomodulators: Abatacept (Orencia®), Certolizumab Pegol (Cimzia®), Golimumab (Simponi Aria®), Tocilizumab (Actemra®), Ustekinumab (Stelara®), and Vedolizumab (Entyvio®) will be removed.
- The above-listed medical drug policies will be added individually.

There are no changes in the prior authorization (PA) requirements or medical review criteria associated with these policies. For all six of the medical drugs, PA will continue to be required for non-oncologic indications only.

Medical Services that require Pre-Certification/Pre-Authorization/Notification

Only services on the PA lists require pre-certification/pre-authorization/notification. Do not request authorization for services not on the PA lists. Follow the steps below to review the list of services that require a PA:

1. Access the 'Provider Section' of the Blue Cross website at providers.bluecrossmn.com
2. Under 'Tools and Resources' select 'Medical policy' and then acknowledge the Acceptance Statement.
3. Click on the '+' next to 'Utilization Management' and under the 'Precertification Lists' select the 'Commercial Pre-Certification/Pre-Authorization/Notification List'

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.